Research

Hormonal

Liraglutide monotherapy significantly improves glycemic control (reducing A1C and fasting plasma glucose) and lowers body weight in patients with type 2 diabetes without causing hypoglycemia.

For patients with Type 2 Diabetes, Liraglutide is a once-daily injection that effectively lowers blood sugar (A1C) and promotes weight loss without the risk of dangerous low blood sugar levels. While gastrointestinal side effects like nausea are common initially, they tend to subside, and the clinical benefits for glycemic control and weight management are significant.

GoodSupportsHIGH confidence
The present study demonstrated sustained effect of the long-acting GLP-1 analog liraglutide on glycemic control in patients with type 2 diabetes without any major or minor hypoglycemic episodes... Furthermore, in spite of improved glycemic control, which is often associated with an increase in body weight, a dose-dependent decrease in body weight was seen.
Tina Vilsbøll et al. · Diabetes Care · 2007

Why this rating

Double-blind, randomized, placebo-controlled trial with statistically significant results (P < 0.0001) for primary endpoints.

Source

Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes

Tina Vilsbøll et al. · Diabetes Care · 2007

DOI 10.2337/dc06-2593

rct · n=377Cited 471×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →